Cyclacel's Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting
Cyclacel's Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -
- 新型CDK2/9抑制劑fadraciclib引發了一個新的針對癌症的作用機制 -
BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, "Cyclacel" or the "Company"))))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company's cyclin-dependent kinase (CDK) 2/9 inhibitor, as a novel treatment for metastatic colorectal cancer (CRC). The data show that fadraciclib substantially inhibited growth, triggered apoptosis, and induced anaphase catastrophe in CRC patient-derived organoids (PDOs) and xenografts (PDX). The data were presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL.
新澤西州伯克利高地，2024年6月4日（環球新swire） - 生物藥公司Cyclacel Pharmaceuticals, Inc.（納斯達克:CYCC，納斯達克:CYCCP，"Cyclacel"或"公司"）正在開發基於癌細胞生物學的創新藥物，今天宣佈獨立研究者展示了fadraciclib的臨床前數據，該藥物是該公司的環狀依賴性激酶（CDK）2/9抑制劑，作爲一種新的治療轉移性結直腸癌（CRC）的療法具有治療潛力。數據顯示，fadraciclib在CRC患者源性器官樣和異種移植物中能夠顯著抑制生長，觸發細胞凋亡，引發分裂期災難。該數據在美國臨床腫瘤學協會（ASCO）年度會議於2024年5月31日至6月4日在伊利諾伊州芝加哥市的海報展示中披露。
譯文內容由第三人軟體翻譯。